Isabel Echavarria retweetledi
🔬 Metachronous contralateral breast cancer risk and anthracyclines-based chemotherapy: data from the GEICAM registry “El Álamo”.
🙌 Today at #ESMO25 Congress, @GEICAM is excited to present new results exploring the association between neo-adjuvant anthracycline-based chemotherapy and the risk of developing metachronous contralateral breast cancer and second non-breast primary cancer.
📝 Using data from ‘El Álamo’, the GEICAM national breast cancer registry that collects comprehensive real-world clinical information from patients treated across Spain, Dr. Miguel Martín, who served as GEICAM’s President for 30 years until 2025, presents results from this study that provides valuable insights into the long-term outcomes of breast cancer survivors.
📈 The analysis assessed whether exposure to anthracyclines in the neo-adjuvant setting is associated with an increased or differential risk of a second primary tumor. Understanding these potential associations is essential for optimizing therapeutic strategies and refining survivorship care.
🧑⚕️ These findings contribute to the ongoing effort to identify treatment-related factors influencing second cancer risk and to enhance personalized follow-up approaches for patients with early-stage breast cancer.
➡️ You can find all the information about this poster here:
geicam.org/wp-content/upl…
#ESMO2025 #ESMO #BreastCancer #Oncology #CancerResearch
English
